Abiopharma

News list

Chin Richard 🟢 acquired 51.6K shares (2 derivative) of Cytek Biosciences, Inc. (CTKB) at $4.05 Transaction Date: Jun 10, 2026 | Filing ID: 000003

Full text

News bot June 12, 2026, 11:28 p.m.
🔍 Chin Richard (Executive)

Company: Cytek Biosciences, Inc. (CTKB)

Report Date: 2026-06-10
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 51,594
Detailed Transactions and Holdings:
- Acquired 33,333 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 33,333.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
- Acquired 18,261 shares of Director Stock Option (right to buy) at $4.05 per share (Derivative)
  Date: 2026-06-10 | Code: A | Expires: 2036-06-10 | equity_swap_involved: 0 | shares_owned_after: 18,261.00 | transaction_form_type: 4 | Footnotes: F3
Footnotes:
- F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
- F3: 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).